Interim report

January 1 – March 31, 2018

The first quarter in figures

  •  Net sales amounted to TSEK 1,939 (1,755).
  •  The loss after tax amounted to TSEK 9,656 (11,615).
  •  The loss per share amounted to SEK 0.58 (1.40).
  •  The cash flow from current operations was negative in the amount of TSEK 9,682 (11,981).
  •  The gross margin was 46.4% (26.5%).
  •  Electrode sales in volume increased by 1% and reached 4,134 (4,096) units. Repeat sales of electrodes increased by 24%.

Important events during the quarter

  •  The primary market Germany showed a recovery in the quarter with sales in value up by 14% and electrode sales volume up by 9%.
  •  Market and reimbursement activities now up and running in the New York area.

Important events after the end of the period

  • The notice to attend the AGM 2018 was published.
  • The annual report 2017 was published.
  • The first Nevisense article by US researchers was published by Svoboda, Rigel et al. in SKIN, The journal of cutaneous medicine. 
Apr 1 2016 -
Jan 1 - Mar 31 Mar 31 2017 Jan 1 - Dec 31
THE GROUP 2018 2017 Rolling-12 2017
Net sales, SEK ths 1 939 1 755 7 043 6 859
Gross margin, % 46,4% 26,5% 40,6% 35,4%
Equity/Asset ratio, % 91,9% 90,7% 91,4% 90,5%
Net indebtness, multiple 0,09 0,10 0,09 0,11
Cash equivalents, SEK ths 95 542 72 627 95 542 110 015
Cashflow from operating activities, SEK ths -9 682 -11 981 -41 880 -44 180
Earnings per share (before and after dilution), SEK -0,58 -1,40 -3,83 -5,00
Shareholder's equity per share, SEK 6,38 9,79 8,84 13,63
Average number of shares, 000' 16 618 8 285 10 576 8 493
Number of shares at closing of period, 000' 16 618 8 285 16 618 16 618
Share price at end of period, SEK 7,45 19,08 7,45 7,80
Number of sold electrodes, pieces 4 134 4 096 16 742 16 704
Average number of employees 20 22 21 21

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on May 9, 2018.

This interim report has not been subject to review by the Company’s auditors. 

Contact person:

Michael Colérus, CFO

For more information, please contact: 
Simon Grant, CEO SciBase 
Phone: +46 72 887 43 99 
Email: simon.grant@scibase.com

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and now also a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com.

Tags:

About Us

SciBase is a Swedish medical technology company founded in 1998 that has developed Nevisense, a point-of-care device for the accurate detection of malignant melanoma. Nevisense has emerged from more than 20 years of research at Karolinska Institute in Stockholm and at SciBase. The device is designed to be provide additional information when evaluating lesions with a suspicion of melanoma. Nevisense is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. The CE-marked system consists of an electrode on a hand-held probe connected to a small portable device performing the analysis and displaying the result. A video describing the Nevisense method is available on: www.scibase.se/en/the-nevisenseproduct and further information is also available on www.scibase.com.

Subscribe

Documents & Links